Molecular approaches to ependymoma: The next step(s)

Current Opinion in Neurology

Volumn 25, Issue 6, 2012, Pages 745-750

  Witt, Hendrik ^a,b   Korshunov, Andrey ^a,b   Pfister, Stefan M ^a,b   Milde, Till ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

ependymoma; in vivo models; molecular subgroups; preclinical testing

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; LAMININ ALPHA2; MITOGEN ACTIVATED PROTEIN KINASE; MK 0752; PLATELET DERIVED GROWTH FACTOR; TEMOZOLOMIDE; TENASCIN; VASCULOTROPIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHROMOSOME 1Q; CHROMOSOME ANALYSIS; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; CONSENSUS; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE MODEL; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; EPENDYMOMA; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GLIA CELL; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; MITOCHONDRIAL RESPIRATION; MOLECULAR BIOLOGY; NEURAL STEM CELL; NONHUMAN; POSTERIOR CRANIAL FOSSA TUMOR; POSTERIOR FOSSA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; EPENDYMOMA; GENETIC MARKERS; HUMANS; MICE;

EID: 84870064154     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328359cdf5     Document Type: Review

References (28)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109. (Pubitemid 47103521)
2. Ellison DW, Kocak M, Figarella-Branger D, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 2011; 10:7.
3. Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010; 466:632-636.
4. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005; 8:323-335. (Pubitemid 41443417)
5. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011; 20:143-157.
6. Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 2010; 28:3182-3190.
7. Atkinson JM, Shelat AA, Carcaboso AM, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011; 20:384-399.
8. Puget S, Grill J, Valent A, et al. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 2009; 27:1884-1892.
9. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 2000; 177:72-82.
10. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006; 12 (7 Pt 1): 2070-2079.
11. Kilday JP, Mitra B, Domerg C, et al. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG). Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res 2012; 18:2001-2011.
12. Grill J, Avet-Loiseau H, Lellouch-Tubiana A, et al. Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genet Cytogenet 2002; 136:121-125. (Pubitemid 35292023)
13. Godfraind C, Kaczmarska JM, Kocak M, et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol 2012; 124:247-257.
14. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 2002; 161:2133-2141. (Pubitemid 35434859)
15. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002; 86:929-939. (Pubitemid 34271030)
16. Wani K, Armstrong TS, Vera-Bolanos E, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 2012; 123:727-738.
17. Milde T, Hielscher T, Witt H, et al. Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 2012. doi: 10.1111/j.1750-3639.012.00600.x. [Epub ahead of print]
18. Andreiuolo F, Puget S, Peyre M, et al. Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro Oncol 2010; 12:1126-1134.
19. Costa FF, Bischof JM, Vanin EF, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One 2011; 6:e25114.
20. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003; 163:1721-1727. (Pubitemid 37310002)
21. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006; 24:5223-5233. (Pubitemid 46631366)
22. Rogers HA, Kilday JP, Mayne C, et al. Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathol 2012; 123:711-725.
23. Guan S, Shen R, Lafortune T, et al. Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy. Neuro Oncol 2011; 13:748-758.
24. Yu L, Baxter PA, Voicu H, et al. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol 2010; 12:580-594.
25. Senetta R, Miracco C, Lanzafame S, et al. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes. Neuro Oncol 2011; 13:176-183.
26. Servidei T, Meco D, Trivieri N, et al. Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models. Int J Cancer 2012; 131:E791-E803.
27. Milde T, Kleber S, Korshunov A, et al. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol 2011; 122:637-650.
28. Fouladi M, Stewart CF, Olson J, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 2011; 29:3529-3534.